How do you relieve constipation on tirzepatide or semaglutide?
The NHS's general constipation advice is fluids, gradually added fibre and daily activity. One UK bulk-forming laxative label excludes drug-slowed gut movement, so ask a pharmacist. US labels report constipation in 11% to 17% on Zepbound (tirzepatide) against 5% on placebo. On Wegovy (semaglutide) 2.4 mg it was 24% against 11%. Severe belly pain or persistent vomiting needs emergency care.
How common is constipation on tirzepatide and semaglutide?
In US label weight-loss trials, 11% to 17% on Zepbound had constipation, against 5% on placebo. On Wegovy 2.4 mg it was 24%, against 11%.1,2
Rates were lower in US label diabetes trials. They were 6% to 7% on Mounjaro against 1%, and 3% to 5% on Ozempic against 1.5%.3,4
In the semaglutide 2.4 mg trials, a typical bout lasted 47 days, against 35 on placebo. The authors say this may reflect effects on gut movement. Constipation stayed more common than on placebo for all 68 weeks.5
The NHS says you are likely constipated if you have had fewer than 3 poos in the last week.6
Other side effects are in your country’s guide.
What helps first?
The NHS advises plenty of fluids, fibre added gradually and a daily walk or run, and a difference may come within a few days or a few weeks.6
A 2025 US advisory for GLP‑1 users also puts fluids and food fibre first, including prunes or other dried fruit.7 A small, partly randomised US trial with no placebo arm, not of GLP‑1 users, found straining eased over 4 weeks with 2 green kiwifruit or 100 g of prunes a day.8
Which laxative, and for how long?
The NHS usually suggests a bulk-forming laxative first, but that advice is general, not for GLP‑1 users. One UK psyllium label rules it out with blockage, faecal impaction or drug-slowed gut movement, so ask a pharmacist first.10,25 The US guideline’s strongest recommendation among osmotic laxatives is for polyethylene glycol.11
Bulk-forming laxatives take up to 3 days and osmotic ones 2 to 3 days. Stool softeners take 12 hours to 3 days, and stimulants 6 to 12 hours. The NHS advises plenty of fluids with bulk-forming and osmotic types.10
Health Canada says to take bulk-forming products with a full glass of water, never dry.13
The US gut-specialist guideline strongly recommends polyethylene glycol, with benefit shown over 6 months. Side effects include bloating, loose stool, gas and nausea.11
Magnesium oxide gets a conditional recommendation, but not for people with kidney problems. It was not written for GLP‑1 users.11
The NHS says not to take a bought laxative for over 7 days. That limit is for products bought without a prescription.10 Longer use is for a doctor to direct.12
The NHS says to get advice after 3 days without results. Overuse can cause dehydration, low potassium or a blocked bowel.10
Health Canada says not to use laxatives with abdominal pain, nausea, fever or vomiting.12 Nausea is common on GLP‑1 medicines, so ask a pharmacist if you have it.1,2
Changing a GLP‑1 dose is the prescriber’s decision. The US labels describe delaying a Wegovy dose step or a lower Zepbound maintenance dose.1,2
When is constipation on a GLP‑1 dangerous?
The US Zepbound, Mounjaro, Wegovy and Ozempic labels list ileus, intestinal obstruction and severe constipation with faecal impaction. These come from reports after approval.1,2,3,4
Ileus is a stalled bowel, and intestinal obstruction is a blocked one. These reports are voluntary, so their frequency can’t be reliably estimated.3
The NHS says long-term constipation can cause a build-up of poo in the rectum. The main symptom is diarrhoea leaking around it, so loose stool after days of constipation is not always relief. It needs medical treatment. The NHS says not to remove it yourself.6
What do people on GLP‑1 medicines report about constipation?
From public patient forums: 1026 Reddit threads in r/Zepbound, r/WegovyWeightLoss, r/Mounjaro, r/Semaglutide, r/mounjarouk and r/Ozempic, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Partly matches the trial Several say it began in the first weeks, and several after a dose increase. In the semaglutide trials, stomach and gut side effects overall were most common during or shortly after dose increases. The trial did not report this for constipation alone.5
- Matches the label Several describe emergency care or imaging for a blockage or stuck stool, some second-hand. The US labels list intestinal obstruction and faecal impaction among reports after approval.1,2
- Matches the NHS Several swing between constipation and loose stools, and a few suspect or were told of overflow around stuck stool. The NHS says leaking diarrhoea is the main symptom of faecal impaction.6
- Matches the NHS and a US advisory Several blame other medicines, such as opioids or ondansetron. The NHS names opioid painkillers, and a US advisory says ondansetron can worsen constipation.6,7
- No study found Several link eating less to fewer or smaller stools. Some accept this if comfortable, and others dispute it.
Advice people share
- Matches the NHS and a trial Many drink more, several add fibre slowly, and several eat prunes or kiwifruit. The NHS advises fluids and gradual fibre. A small US trial, not of GLP‑1 users, found prunes and kiwifruit eased straining.6,8
- Matches the US guideline Many use polyethylene glycol, with mixed results, or magnesium products, with disagreement about forms. The US guideline strongly backs polyethylene glycol and conditionally backs magnesium oxide only, but not with kidney problems. It does not cover GLP‑1 users specifically.11
- NHS says otherwise A few take stimulant laxatives such as senna for weeks. The NHS says not to take senna for more than 7 days unless a doctor or pharmacist has advised it.14
- Label says otherwise Several skip or change GLP‑1 doses on their own. The US labels leave dose changes for side effects to the prescriber.1,2
In your country
Brand names, the constipation detail each label prints and the emergency number differ by country.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian Wegovy Product Information reports constipation in 24.2% against 11.1% on placebo in its text, and 21.8% against 10.2% in its table for trials up to 2.4 mg. It lists ileus, intestinal obstruction and severe constipation including faecal impaction after approval.26 We could not open the Australian Mounjaro information, so this page relies on the US label for Mounjaro.3
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: Canada’s Zepbound monograph reports 16.8%, 14.1% and 10.8% on 5, 10 and 15 mg, against 5.2% on placebo. Its patient information lists ileus as a serious side effect.23
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The EU Mounjaro label gives constipation as very common in weight-management trials and common in type 2 diabetes trials. It gives no percentage for the weight trials. The EU Mounjaro side-effect table does not list ileus or intestinal obstruction.22 The EU Wegovy label lists intestinal obstruction, including ileus, from reports after sale.21
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The EU Mounjaro label gives constipation as very common in weight-management trials and common in type 2 diabetes trials. It gives no percentage for the weight trials. The EU Mounjaro side-effect table does not list ileus or intestinal obstruction.22 The EU Wegovy label lists intestinal obstruction, including ileus, from reports after sale.21
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We found no public Indian label, so this page relies on the US labels.1,2 An Indian government backgrounder names bowel obstruction among the severe complications of GLP‑1 medicines.24
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We found no public Saudi label text to check, so this page relies on the US labels.1,2
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We found no public UAE label text to check, so this page relies on the US labels.1,2
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK Mounjaro leaflet lists constipation as very common in weight management and common in type 2 diabetes. It does not list bowel obstruction or ileus. The UK Wegovy leaflet lists bowel obstruction, frequency not known.19,20
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor if you can’t pass gas or your belly stays swollen. Do the same for unexplained belly pain that won’t go away, or no bowel movement in 3 days.9,18
Read the full picture
Related questions
Sources
- Eli Lilly. Zepbound (tirzepatide) US prescribing information, revised 8/2026, sections 2.1, 6.1 and 6.2. US label. DailyMed
- Novo Nordisk. Wegovy (semaglutide) injection and tablets, US prescribing information, revised 6/2026, sections 2.2, 6.1 and 6.2. US label. DailyMed
- Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised 8/2026, sections 6.1 and 6.2. US label. DailyMed
- Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information, revised 5/2026, sections 6.1 and 6.2. US label. DailyMed
- Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes, Obesity and Metabolism 2022;24:94–105. Trials funded by Novo Nordisk. PMC
- NHS. Constipation. Page last reviewed 26 Oct 2023. nhs.uk
- Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. American Journal of Clinical Nutrition 2025;122:344–367. Several authors declare advisory or speaker roles with Novo Nordisk or Eli Lilly. PMC
- Chey SW et al. Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US patients with chronic constipation. American Journal of Gastroenterology 2021;116(6):1304–1312. 79 adults, 4 weeks; not a GLP‑1 study. PubMed
- MedlinePlus (US National Library of Medicine). Constipation – self-care. Review date 7/15/2024. medlineplus.gov
- NHS. Laxatives. Page last reviewed 30 Apr 2026. nhs.uk
- Chang L et al. AGA–ACG clinical practice guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology 2023;164:1086–1106. Funded by the two societies, with no industry support. PMC
- Health Canada. Laxatives: general labelling standard for non-prescription drugs. canada.ca
- Health Canada. Laxatives: bulk-forming labelling standard for non-prescription drugs. canada.ca
- NHS. Senna. Page last reviewed 24 Sep 2026. nhs.uk
- MedlinePlus (US National Library of Medicine). Recognizing medical emergencies, warning signs from the American College of Emergency Physicians. Reviewed Jan 8, 2025. medlineplus.gov
- MedlinePlus (US National Library of Medicine). Abdominal pain. Reviewed Jan 13, 2026. medlineplus.gov
- Emergency Care BC (Provincial Health Services Authority, Canada). Constipation patient sheet. Last reviewed June 4, 2024. emergencycarebc.ca (PDF)
- MedlinePlus (US National Library of Medicine). Intestinal obstruction. Reviewed Apr 27, 2026. medlineplus.gov
- Novo Nordisk. Wegovy (semaglutide) UK patient information leaflet, revised 08/2026. UK label. medicines.org.uk (emc)
- Eli Lilly. Mounjaro KwikPen (tirzepatide) UK patient information leaflet, revised Aug 2026. UK label. medicines.org.uk (emc)
- European Medicines Agency. Wegovy (semaglutide) EU product information, section 4.8. EU label. ema.europa.eu (PDF)
- European Medicines Agency. Mounjaro (tirzepatide) EU product information, section 4.8. EU label. ema.europa.eu (PDF)
- Eli Lilly Canada. Zepbound (tirzepatide) Product Monograph, Date of Authorization June 11, 2026, Table 2 and Patient Medication Information. Canadian label. pdf.hres.ca (PDF)
- PIB Research, Government of India. GLP-1 drugs: use, risks, and regulation. Apr 1, 2026. pib.gov.in (PDF)
- Fybogel Hi-Fibre Orange (ispaghula husk) UK summary of product characteristics, sections 4.3 and 4.4, text revised 11/12/2020. UK label. medicines.org.uk (emc)
- Novo Nordisk. Wegovy (semaglutide) Australian Product Information, section 4.8. Australian label. medsinfo.com.au (PDF)
- Healthdirect Australia. Bowel obstruction. Last reviewed September 2024. healthdirect.gov.au
Last checked Nov 8, 2026 · Next review due Nov 8, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 8 or 9, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write